ASX News

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)

Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation of  68Ga-PSMA-11), a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA) for the imaging of prostate cancer using Positron Emission Tomography (PET), has been accepted for filing by the United States Food and Drug Administration (FDA).

Telix submitted its NDA for TLX591-CDx on 23rd September 2020 seeking an indication for the diagnostic imaging of prostate cancer, including from the early pre-treatment setting through to the later stages of advanced disease. In its submission, Telix included a request for priority review, the outcome of which Telix expects to be notified around 10th December 2020.

Telix’s Chief Medical Officer, Dr Colin Hayward said, “The use of 68Ga-PSMA PET imaging is rapidly becoming the standard of care for prostate cancer imaging across a broad range of clinical settings. PSMA imaging is already included in the leading clinical practice guidelines in the United States and Europe, based on evidence that definitively demonstrates superiority over conventional imaging. This is highly supportive of rapid adoption of Telix’s product upon approval.”

Telix CEO, Dr Christian Behrenbruch said, “We are delighted to have achieved this significant milestone with the FDA’s acceptance for filing of the first commercial NDA for PSMA imaging in the United States. This represents a major step towards our goal of providing this highly anticipated product to patients in the United States and beyond. From acquiring ANMI and its advanced chemistry platform in December 2018, to successfully filing an NDA less than two years later, represents an extraordinary achievement by the Telix team. We now look forward to working with the FDA to bring TLX591-CDx to American patients living with prostate cancer as expeditiously as possible.”

Telix’s NDA submission for TLX591-CDx included clinical data from over 600 patients obtained from studies performed by Telix or in collaboration with research partners. The NDA also included clinical evidence reported in the peer-reviewed medical literature, a significant proportion of which originated from research undertaken at leading academic centres including the University of California, Los Angeles (USA), the Peter MacCallum Cancer Centre (Australia) and Heidelberg University Hospital (Germany).

Read the full ASX release here.

More Articles

ASX News

Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent

Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s...

ASX News

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Melbourne (Australia) – 12 April 2021. Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12...

ASX News

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31st March 2021. Telix announces it has completed an agreement with Grand River...

Corporate Spotlight

Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

ASX News

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial supply...

Corporate Spotlight

Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility

8th March 2021 – Corporate Spotlight | Sébastien Linard joins Telix as General Manager of Telix’s European Manufacturing in Seneffe,...

ASX News

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial...

ASX News

Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.

ASX News

Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan

Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a...

ASX News

Telix FY2020 Results and Company Update Conference Call

Melbourne (Australia) – 16th February 2021. Telix to present the Company’s FY2020 results together with an update on Telix’s operations.

ASX News

Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

Melbourne (Australia) and Liège (Belgium) – 16th February 2021. Telix announces the Ministry of Health of the Czech Republic is...

ASX News

Telix and Heidelberg University Hospital to Develop Next Generation Theranostics

Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop...

Corporate Spotlight

Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium

3rd February 2021 | Corporate Spotlight – Recording of Industry Leaders’ Round-Table Discussion at SNMMI Mid-Winter Symposium: Ga-68 PSMA-11: Advances...

ASX News

First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...

Corporate Spotlight

Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific

22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific

Corporate Spotlight

ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target

Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...

ASX News

Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...

ASX News

Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance

Melbourne (Australia) – 16th December 2020. [Article updated with new video 16th February 2021] Telix Pharmaceuticals announces collaboration with Mauna...

ASX News

Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging

Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...

ASX News

Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data

Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...

ASX News

Telix Granted TGA Priority Review for Prostate Cancer Imaging

Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...

ASX News

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...

ASX News

Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process

Melbourne (Australia) – 14 April 2021. Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced...